FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC

Jie Liu,Yeling Ouyang,Zijin Xia,Wenhao Mai,Hongrui Song,Fang Zhou,Lichun Shen,Kaiting Chen,Xiaochen Li,Shi-Min Zhuang,Jing Liao
DOI: https://doi.org/10.1007/s13402-023-00888-5
IF: 7.051
2023-10-19
Cellular Oncology
Abstract:PD-1 targeted immunotherapy has imparted a survival benefit to advanced head and neck squamous cell carcinoma (HNSCC), but less than 20% patients produce a durable response to this therapy. Here we aimed to investigate the potential biomarkers for predicting the clinical outcome and resistance to PD-1 targeted immunotherapy in HNSCC patients, and to examine the involvement of FAP + cancer-associated fibroblasts (CAFs).
oncology,pathology,cell biology
What problem does this paper attempt to address?